TOP TEN perturbations for P23769 (Homo sapiens)

Organism: Homo sapiens
Gene: P23769
Selected probe(set): 209710_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P23769 (209710_at) across 5392 perturbations tested by GENEVESTIGATOR:

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):3.8984308
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 ?C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 ?C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 ?C in 6-well plates.

stem cell differentiation study 46 (BMP4, inhibitors) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):3.12636
Number of Samples:3 / 3
Experimental stem cell differentiation study 46 (BMP4, inhibitors)
Extraembryonic cells differentiated from WA09 cells in chemically defined medium supplemented with BMP4 and inhibitors of activin and FGF2. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml), an inhibitor of Alk4/5/7 receptors (type I Activin receptor-like kinase), SB431542 (10uM), and an inhibitor of FGF receptors, SU5402 (10uM), for 3-4 days.
Control normal embryonic stem cell sample (WA09)
WA09 embryonic stem cells cultivated in chemically defined medium (CDM). Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then further cultivated in CDM alone for 3-4 days. CDM consists of 50% Iscove?s Modified Dulbecco?s Medium and 50% F12 Ham?s nutrient mixture. It is devoid of serum and supplemented with insulin (7 ug/ml), transferrin (15 ug/ml), monothioglycerol (450 uM) and serum albumin (5 mg/ml).

lung adenocarcinoma study 6 (K-RAS mut) / adjacent lung tissue

Relative Expression (log2-ratio):-2.7679539
Number of Samples:6 / 20
Experimental lung adenocarcinoma study 6 (K-RAS mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

stem cell differentiation study 46 (BMP4) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):2.7640886
Number of Samples:3 / 3
Experimental stem cell differentiation study 46 (BMP4)
Mesendoderm cells differentiated from WA09 cells in chemically defined medium (CDM) supplemented with BMP4. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml) for 3-4 days.
Control normal embryonic stem cell sample (WA09)
WA09 embryonic stem cells cultivated in chemically defined medium (CDM). Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then further cultivated in CDM alone for 3-4 days. CDM consists of 50% Iscove?s Modified Dulbecco?s Medium and 50% F12 Ham?s nutrient mixture. It is devoid of serum and supplemented with insulin (7 ug/ml), transferrin (15 ug/ml), monothioglycerol (450 uM) and serum albumin (5 mg/ml).

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):2.637991
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

lung adenocarcinoma study 3 (negative) / normal lung tissue

Relative Expression (log2-ratio):-2.6303864
Number of Samples:9 / 3
Experimental lung adenocarcinoma study 3 (negative)
Primary lung adenocarcinoma samples, with bone marrow negative for early disseminated tumor cells (DTCs). The presence of DTCs can predict the subsequent occurrence of overt metastasis and survival in lung cancer.
Control normal lung tissue
Normal lung tissue.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):2.5624876
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

hepatocyte-like cell differentiation study 1 (10d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):2.5177126
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (10d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

endometriosis study 2 / normal endometrium tissue

Relative Expression (log2-ratio):-2.5168047
Number of Samples:10 / 10
Experimental endometriosis study 2
Endometrium tissue from patients with endometriosis.
Control normal endometrium tissue
Normal endometrium tissue.

prostate cancer study 1 (meta.) / benign prostate tissue

Relative Expression (log2-ratio):-2.5082932
Number of Samples:6 / 6
Experimental prostate cancer study 1 (meta.)
Metastatic prostate cancer samples.
Control benign prostate tissue
Benign prostate samples.